News | May 15, 2007

Positive Statistical Analysis from Synthetic Blood's Oxycyte Traumatic Brain Injury Trial

May 16, 2007 — Synthetic Blood International Inc. announced positive data from a statistical analysis of its Phase IIa study with Oxycyte in patients with traumatic brain injury. In line with preliminary study results announced in December 2006, statistical results confirmed that the primary endpoint of increasing patients' oxygen tension levels compared with baseline was met.

Data also show a decrease in patient glucose and lactate/pyruvate (LP) ratio, consistent with increased glucose metabolism. Patients in this trial were stabilized with either 50 percent or 100 percent oxygen. Data determined that results of both treatment arms were favorable, with statistically significant differences in some data between the two treatment arms.

"This analysis further validates our initial study findings that Oxycyte is more effective in increasing brain oxygen tension levels and impacting other brain chemistries that contribute to more favorable clinical outcomes in patients with traumatic brain injury, than breathing either 100 percent or 50 percent oxygen alone," said Robert Nicora, president and CEO. "Based on these positive results, we are working with Virginia Commonwealth University (VCU) to develop a protocol for a multicenter, controlled Phase IIb trial that could enroll up to 100 patients with traumatic brain injury. Researchers at VCU are drafting a manuscript with the Phase IIa TBI results to submit to a scientific journal.

"We continue active discussions with several sources for financing the company," Mr. Nicora continued. "If we are successful in these discussions, the receipt of additional funding will enable us to move forward with our Phase IIb program and other development activities with Oxycyte, which include plans to initiate a cardiac ischemia study in an animal model."

For more information visit www.sybd.com.

Related Content

Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
Technology | Clinical Decision Support | February 14, 2018
The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first ...
Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Videos | Artificial Intelligence | December 19, 2017
A post-game roundup by ITN Contributing Editor Greg Freiherr and ITN Editor Dave Fornell on the key trend of artifici
iCAD's PowerLook Tomo Detection Experiences Growing Adoption
News | Mammography | December 14, 2017
December 14, 2017 — iCAD Inc.
Infervision Launches AI Platform to Help Radiologists Diagnose Stroke Faster
Technology | Computed Tomography (CT) | November 28, 2017
Infervision is introducing what it calls the first and only artificial intelligence (AI) platform to help radiologists...
Kansas City Radiology Center Employs iCAD PowerLook Tomo Detection for DBT
News | Computer-Aided Detection Software | November 10, 2017
November 10, 2017 — Imaging for Women, a leading radiology center in Kansas City, Mo., announced it is now using iCAD
Overlay Init